Hyperkalemia Epidemiology Forecast 2025-2034

Hyperkalemia is a medical condition characterized by the presence of high levels of potassium in the blood (above 5.5 mmol/L). Studies suggest that less than 5% of the general population is affected by hyperkalemia, with risk factors including advanced age, kidney failure, diabetes mellitus, and heart failure, among others.

Hyperkalemia Epidemiology Forecast Report Coverage

Expert Market Research's “Hyperkalemia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hyperkalemia. It projects the future incidence and prevalence rates of hyperkalemia across various populations. The study covers age and type as major determinants of the hyperkalemia-affected population. The report highlights patterns in the prevalence of hyperkalemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hyperkalemia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hyperkalemia: Disease Overview

In hyperkalemia, the potassium levels in the blood go above 5.5 mmol/L. In case the potassium level goes above 6.5 mmol/L, heart problems may arise that require prompt medical attention. It is observed that an individual with a chronic kidney disease is three times more likely to develop hyperkalemia. Mild hyperkalemia symptoms include diarrhea, abdominal pain, nausea, and vomiting, among others.

Hyperkalemia: Treatment Overview

Treatment for hyperkalemia primarily focuses on lowering serum potassium levels. Medications for hyperkalemia are used to stabilize cardiac function, shift potassium into cells, and eliminate excess potassium from the body. Calcium gluconate or calcium chloride is commonly administered intravenously to stabilize the heart and prevent arrhythmias. Cation-exchange resins like sodium polystyrene sulfonate (Kayexalate) are typically prescribed for potassium removal.

Epidemiology

The hyperkalemia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for hyperkalemia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hyperkalemia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Hyperkalemia is reported to affect less than 5% of the global population. It is estimated that hospitalized patients in regions such as England, Israel, and Australia, experience the medical condition around 10% of the time.
• According to a research article published in the International Journal of Nephrology (2024), the annual prevalence of hyperkalemia is estimated to be 4.41%.
• As per the systematic review published in Clinical Kidney Journal (2022), the rates of hyperkalemia were reported to be the highest in patients with acute kidney injury (24.3%), kidney transplants (21.8%), and end-stage kidney disease (21.5%).
• Studies show that advanced kidney disease is a common cause of hyperkalemia, with high potassium levels affecting nearly 40 to 50% of chronic kidney disease patients.

Country-wise Hyperkalemia Epidemiology

The hyperkalemia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hyperkalemia varies significantly between countries owing to the differences in prevalence of chronic diseases, dietary patterns, access to healthcare, and use of medications that affect potassium levels, among others. In the United States, a meta-analysis reported the prevalence of hyperkalemia to be 6.3% in the adult population.

Country Specific Stats:

Country

Prevalence (Unit)

United States

United Kingdom

Germany

Italy

France

Spain

Japan

India

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hyperkalemia based on several factors.
• Hyperkalemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of hyperkalemia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hyperkalemia epidemiology in the 8 major markets?
• What will be the total number of patients with hyperkalemia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hyperkalemia in the 8 major markets in the historical period?
• Which country will have the highest number of hyperkalemia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hyperkalemia during the forecast period of 2025-2034?
• What are the currently available treatments for hyperkalemia?
• What are the disease risks, signs, symptoms, and unmet needs of hyperkalemia?

Related Reports

X-linked Hypophosphatemia (XLH) Drug Pipeline Analysis Report